310 related articles for article (PubMed ID: 31796212)
1. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
Stewart S; Tallon A; Taylor WJ; Gaffo A; Dalbeth N
Semin Arthritis Rheum; 2020 Apr; 50(2):303-313. PubMed ID: 31796212
[TBL] [Abstract][Full Text] [Related]
2. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
[TBL] [Abstract][Full Text] [Related]
3. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare.
Tai V; Gow P; Stewart S; Satpanich P; Li C; Abhishek A; Dalbeth N
Semin Arthritis Rheum; 2024 Apr; 65():152367. PubMed ID: 38215627
[TBL] [Abstract][Full Text] [Related]
4. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
[TBL] [Abstract][Full Text] [Related]
5. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
6. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Joint Bone Spine; 2020 Dec; 87(6):647-651. PubMed ID: 32979555
[TBL] [Abstract][Full Text] [Related]
7. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
Stamp LK; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
J Rheumatol; 2018 Mar; 45(3):419-424. PubMed ID: 29247147
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
9. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
10. When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy.
Choi HK; Zhang Y; Dalbeth N
Nat Rev Rheumatol; 2022 Sep; 18(9):543-549. PubMed ID: 35879610
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Gout and Serum Urate.
Chang K; Hung S
JAMA; 2024 May; 331(20):1767. PubMed ID: 38696185
[No Abstract] [Full Text] [Related]
12. The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials.
Jia E; Yao X; Geng H; Zhong L; Xie J; Xiao Y; Jiang Y; Qiu X; Xiao M; Zhang Y; Tang D; Wei J; Zhang J
Adv Rheumatol; 2022 Jan; 62(1):5. PubMed ID: 35093171
[TBL] [Abstract][Full Text] [Related]
13. Improving outcomes for patients hospitalized with gout: a systematic review.
Russell MD; Clarke BD; Roddy E; Galloway JB
Rheumatology (Oxford); 2021 Dec; 61(1):90-102. PubMed ID: 34247233
[TBL] [Abstract][Full Text] [Related]
14. Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.
Jia E; Hu S; Geng H; Zhu H; Xie J; Xiao Y; Jiang Y; Xiao M; Zhang J
Medicine (Baltimore); 2022 May; 101(18):e29199. PubMed ID: 35550468
[TBL] [Abstract][Full Text] [Related]
15. Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.
Watson L; Belcher J; Nicholls E; Muller S; Mallen C; Roddy E
Arthritis Rheumatol; 2020 Nov; 72(11):1928-1935. PubMed ID: 32767502
[TBL] [Abstract][Full Text] [Related]
16. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
[TBL] [Abstract][Full Text] [Related]
17. The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.
Jatuworapruk K; Grainger R; Dalbeth N; Lertnawapan R; Hanvivadhanakul P; Towiwat P; Shi L; Taylor WJ
Rheumatology (Oxford); 2022 Apr; 61(4):1658-1662. PubMed ID: 34297058
[TBL] [Abstract][Full Text] [Related]
18. Gout: nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy.
Kuritzky L; Panchal R
J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):397-401. PubMed ID: 21133750
[TBL] [Abstract][Full Text] [Related]
19. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
20. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
